Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2013 | 1 |
2014 | 2 |
2015 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
Eur J Cancer. 2014 Sep;50(14):2375-89. doi: 10.1016/j.ejca.2014.06.007. Epub 2014 Jul 24.
Eur J Cancer. 2014.
PMID: 25065293
Free PMC article.
Clinical Trial.
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.
Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.
Irshad S, et al.
Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.
Breast Cancer Res Treat. 2014.
PMID: 24519386
Clinical Trial.
Item in Clipboard
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists.
Ellis P, et al.
Lancet. 2009 May 16;373(9676):1681-92. doi: 10.1016/S0140-6736(09)60740-6.
Lancet. 2009.
PMID: 19447249
Free PMC article.
Clinical Trial.
Item in Clipboard
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C.
Jamal-Hanjani M, et al.
Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23.
Ann Oncol. 2015.
PMID: 26003169
Free article.
Clinical Trial.
Item in Clipboard
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.
Bartlett JM, A'hern R, Piper T, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Bliss JM, Ellis P, Barrett-Lee PJ.
Bartlett JM, et al.
Breast Cancer Res Treat. 2013 Apr;138(3):773-81. doi: 10.1007/s10549-013-2489-y. Epub 2013 Mar 28.
Breast Cancer Res Treat. 2013.
PMID: 23535839
Clinical Trial.
Item in Clipboard
Cite
Cite